Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Curability Of Breast Cancer And The Treatment Of Advanced Disease

V. Guarneri, P. Conte
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
AbstractBreast cancer represents a major health problem, with more than 1,000,000 new cases and 370,000 deaths yearly worldwide. In the last decade, in spite of an increasing incidence, breast cancer mortality has been declining in the majority of developed countries. This is the combined result of better education, widespread screening programmes and more efficacious adjuvant treatments. Better knowledge of breast cancer biology now allows the cosmetic, physical and psychological consequences of radical mastectomy to be spared in the majority of breast cancer patients. Use of the sentinel node technique is rapidly expanding and this will further reduce the extent and the consequences of surgery. Several clinico-pathological factors are used to discriminate between patients at low (<10%), average (10–40%) and high risk of relapse. Nodal status, tumour size, tumour grade and age are accepted universally as important factors to define risk categories. Newer factors such as uPA/PAI-1, HERer2-neu, proliferative indices and gene expression profile are promising and will allow better discrimination between patients at different risk. Endocrine manipulation with tamoxifen, ovarian ablation or both is the preferred option in the case of endocrine-responsive tumours. Tamoxifen administered for 5 years is the standard treatment for postmenopausal patients; tamoxifen plus ovarian ablation is more effective than tamoxifen alone for premenopausal women. Recent data demonstrate that, for postmenopausal patients, the aromatase inhibitors are superior to tamoxifen, with a different safety profile. At present, anastrozole can be used in the adjuvant setting in cases of tamoxifen intolerance or toxicity. Chemotherapy is the treatment of choice for steroid receptor-negative tumours. Polychemotherapy is superior to single agents and anthracycline-containing regimens are superior to CMF. Six courses of FEC or FAC or the sequential administration of four doses of anthracycline followed by four of CMF are the recommended regimens. New regimens including the taxanes have produced a further improvement in risk reduction and are reasonable therapeutic options. The taxanes have been approved for adjuvant therapy in the USA, while European approval is pending. Combined endocrine–chemotherapy is the standard adjuvant treatment in high-risk patients with endocrine-responsive tumours. Endocrine manipulation is usually administered after completion of the chemotherapy programme. For HER2-neu overexpressing tumours, several rapidly accruing trials are exploring the potential additive effect of trastuzumab, a monoclonal antibody directed against the extramembrane portion of the HER2 receptor. Primary chemotherapy is increasingly used in the treatment of locally advanced and operable breast cancer, with increased rates of breast-conserving surgery. A proportion of patients achieve a pathological complete response and these patients have significantly better long-term outcomes. Twenty-five to forty percent of breast cancer patients develop distant metastases. At this stage the disease is incurable; however, treatments can assure a significant prolongation of survival, symptomatic control and maintenance of quality of life. In the case of hormone receptor positivity and in the absence of visceral, life-threatening disease, endocrine manipulation is the treatment of choice. Active treatments include tamoxifen, ovarian ablation, aromatase inhibitors, pure anti-oestrogens and progestins. Aromatase inhibitors are the most active agents, but the choice and the sequence of endocrine therapies are also dictated by prior adjuvant treatment. Chemotherapy has to be preferred in cases of receptor-negative tumours, acquired resistance to hormones and aggressive visceral disease. Combination regimens are usually associated with higher response rates and sometimes survival prolongation, and this approach should be recommended in young patients with good performance status and visceral disease. On the other hand, single agents have a better tolerability profile and should be the treatment of choice when a careful balance between activity and tolerability is needed. For HER2-neu positive tumours, the combination of trastuzumab and chemotherapy is significantly superior to chemotherapy alone in terms of both response rates and survival. Other useful palliative treatments include bisphosphonates for the control of metastatic bone disease and radiotherapy for painful bone lesions or local relapses.
This paper references
10.1200/JCO.20.6.1456
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
I. C. Smith (2002)
10.1200/JCO.2003.09.081
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
M. Citron (2003)
10.1016/S0959-8049(99)00122-7
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
J. Sjöström (1999)
10.1016/S0140-6736(02)09088-8
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
M. Baum (2002)
10.1200/JCO.1996.14.7.2000
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
A. Buzdar (1996)
10.1200/JCO.2004.02.112
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
A. Howell (2004)
10.1056/NEJMOA032312
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
P. Goss (2003)
10.1200/JCO.1999.17.11.3596
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
A. Gennari (1999)
Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer
L. Pusztai (2003)
10.1016/0140-6736(92)90997-H
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
A. Howell (1992)
10.1200/JCO.2001.19.3.628
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
R. A. Brito (2001)
10.1200/JCO.2003.02.063
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I. C. Henderson (2003)
10.1023/A:1008334404825
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.
M. Colleoni (2000)
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
J. Nabholtz (1999)
10.1200/JCO.2003.12.005
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2003)
10.1200/JCO.2001.19.14.3357
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
A. Buzdar (2001)
10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
G. Hortobágyi (1988)
10.1200/JCO.2002.09.002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
10.1056/NEJM198812293192601
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women
I. Henderson (1988)
10.1200/JCO.2003.04.576
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
A. Goldhirsch (2003)
Doxorubicin - induced cardiomiopathy
KS Pawan (1998)
10.1056/NEJM199810013391401
The sentinel node in breast cancer--a multicenter validation study.
D. Krag (1998)
10.1002/cncr.11577
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
L. Zelek (2001)
10.1200/JCO.2000.18.22.3748
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
J. Bonneterre (2000)
10.1200/JCO.2000.18.22.3758
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
J. Nabholtz (2000)
10.1200/JCO.2000.18.11.2234
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
P. Lønning (2000)
10.1200/JCO.1997.15.6.2345
Sentinel lymphadenectomy in breast cancer.
A. E. Giuliano (1997)
10.1007/s002800050664
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center
N. Ueno (1997)
10.1056/NEJMOA040331
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
R. C. Coombes (2004)
10.1016/S0140-6736(97)11423-4
Tamoxifen for early breast cancer: An overview of the randomised trials
O. Abe (1998)
Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.
F. Spyratos (2002)
10.1200/JCO.1996.14.1.46
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
S. Rivkin (1996)
10.1002/cncr.11701
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
L. Rosen (2003)
10.1200/JCO.1996.14.5.1558
Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group.
R. Arriagada (1996)
10.1016/S0360-3016(99)00103-0
Collagen vascular diseases and radiation therapy: a critical review.
B. De Naeyer (1999)
10.1200/JCO.2003.08.017
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
B. Hillner (2003)
10.1016/S1359-6349(03)90702-6
671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)
M. Bontenbal (2003)
10.1056/NEJMOA022794
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
S. Rodenhuis (2003)
10.1200/JCO.1998.16.10.3439
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
R. Fossati (1998)
10.1002/14651858.cd003366.pub2
Taxane containing regimens for metastatic breast cancer.
D. Ghersi (2003)
10.1056/NEJM199511303332203
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.
B. Fisher (1995)
Polychemotherapy for early breast cancer: an overview of the randomised trials
M. Clarke (1998)
10.1056/NEJMOA021967
A gene-expression signature as a predictor of survival in breast cancer.
M. J. van de Vijver (2002)
10.1200/JCO.2001.19.22.4216
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
E. Perez (2001)
Taxane containing regimes for metastatic breast cancer
D. Ghersi (2003)
Fulvestrant versus tamoxifen for the first - line treatment of advanced breast cancer ( ABC ) in postmenopausal women
Robertson JFR (2002)
The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer ( MBC ) in a population based cohort
Chia SKL (2003)
10.1200/JCO.2000.18.8.1668
Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence.
C. Park (2000)
10.1200/JCO.2003.08.013
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients
J. Blum (2001)
10.1016/S0140-6736(96)05023-4
Ovarian ablation in early breast cancer: Overview of the randomised trials
M. Clarke (1996)
10.1056/NEJM199809243391307
Doxorubicin-induced cardiomyopathy.
P. Singal (1998)
10.1056/NEJM199504063321402
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.
J. A. Jacobson (1995)
10.1016/S1053-4296(05)80093-1
Results of Concomitantly Administered Chemoradiation for Locally Advanced Noninflammatory Breast Cancer.
Berg (1994)
10.1200/JCO.2001.19.14.3441
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide for metastatic breast cancer.
C. D. Atkins (2001)
in vivo chemosensitivity-adapted neoadjuvant chemotherapy (docetaxel-doxorubicin-cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: results of the Gepar- trio randomized pilot study
G. Minckwitz (2003)
10.1002/cncr.11745
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer
M. Baum (2003)
10.1097/00000658-199007000-00006
Breast‐conserving Therapy for Macroscopically Multiple Cancers
J. Kurtz (1990)
10.1200/JCO.1998.16.6.2038
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
G. Hortobagyi (1998)
10.1200/JCO.1999.17.2.460
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H. Kuerer (1999)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1200/JCO.2005.10.517
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
E. Mamounas (2005)
10.1200/JCO.2001.19.2.343
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
J. Klijn (2001)
10.1054/bjoc.2000.1461
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
J. Pierga (2000)
10.1200/JCO.2000.18.7.1399
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
M. Kaufmann (2000)
UKCCCR trial of epirubicin and cyclophosphamide ( EC ) vs . epirubicin and taxol ( ET ) in the first line treatment of women with metastatic breast cancer [ abstract ]
J Carmichael (2001)
10.1200/JCO.2001.19.10.2596
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
H. Mouridsen (2001)
10.1200/JCO.2002.11.005
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis
S. Glück (2001)
10.1200/JCO.1988.6.2.261
Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study.
M. Perloff (1988)
10.1097/00001813-200303000-00007
Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial
U. Mey (2003)
10.1002/(SICI)1098-2388(199609/10)12:5<352::AID-SSU11>3.0.CO;2-R
Inflammatory breast cancer: the evolution of multimodality treatment strategies.
W. Gradishar (1996)
10.1093/CARCIN/BGH019
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.
T. Lindahl (2004)
10.1002/1097-0142(197603)37:3<1422::AID-CNCR2820370325>3.0.CO;2-Y
Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy
R. Zucali (1976)
10.1002/cncr.11468
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women
J. Robertson (2003)
6 cycles of epirubicin / docetaxel ( ET ) versus 6 cycles of 5 FU / epirubicin / cyclophosphamide ( FEC ) as first line metastatic breast cancer ( MBC ) treatment
J Bonneterre (2001)
10.1016/S0959-8049(01)80054-X
Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer
M. Ellis (2001)
10.1016/0140-6736(93)90812-U
Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial
London. (1993)
10.1002/0470011815.B2A01039
National Surgical Adjuvant Breast and Bowel Project
B. Fisher (2005)
10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
A. Buzdar (1998)
10.1200/JCO.2003.04.040
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Lumpectomy for breast cancer: an update of the NSABP experience. National Surgical Adjuvant Breast and Bowel Project.
B. Fisher (1992)
Better survival with epirubicindocetaxel ( ET ) combination as first - line chemotherapy in patients with metastatic breast cancer ( MBC ) : final results of a phase II randomized study [ abstract ]
M Tubiana-Hulin (2003)
10.1038/sj.bjc.6601634
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
A. Gennari (2004)
10.1016/0277-5379(90)90113-8
Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial.
U. Veronesi (1990)
10.1038/nm0102-13
The microarray way to tailored cancer treatment
L. V. Veer (2002)
10.1200/JCO.1999.17.5.1413
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy
J. M. Nabholtz (1999)
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
A. Buzdar (2002)
10.1200/JCO.2000.18.19.3360
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
L. Pierce (2000)
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.
J. van Dongen (1992)
10.1200/JCO.1998.16.8.2672
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B. Fisher (1998)
10.1200/JCO.1996.14.9.2552
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
P. Conte (1996)
10.1200/JCO.1997.15.1.207
Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial.
H. Bartelink (1997)
10.1006/SCBI.1998.0083
The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
J. Ross (1999)
10.1159/000181336
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
R. Peto (1988)
10.1007/978-3-642-84745-5_21
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
M. Clarke (1992)
10.1093/ANNONC/MDG069
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
E. Baldini (2003)



This paper is referenced by
Rrp 1 b , a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis
N. P. Crawford (2007)
10.1016/j.ygyno.2011.06.021
Oncolytic virotherapy of breast cancer.
A. Hartkopf (2011)
10.1007/s00432-006-0138-0
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy
T. Vogl (2006)
10.1016/j.canlet.2009.07.005
Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis.
M. Luo (2010)
10.1002/jcb.26848
Calmodulin antagonist enhances DR5‐mediated apoptotic signaling in TRA‐8 resistant triple negative breast cancer cells
Romone M. Fancy (2018)
10.1177/0885328215577892
Preformed chitosan cryogel-biphasic calcium phosphate: a potential injectable biocomposite for pathologic fracture
C. Abueva (2015)
10.6004/JNCCN.2014.0008
Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
D. Seah (2014)
10.1016/j.clinthera.2013.01.011
Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
Romita Das (2013)
10.5505/TJONCOL.2014.1080
Whole brain radiotherapy results of patients with brain metastases and investigation of their prognostic factors
Gokhan Yilmazer (2014)
10.2147/BCTT.S71781
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase
S. Larsén (2014)
10.1586/14737140.4.6.1179
Endocrine therapy and other targeted therapies for metastatic breast cancer
S. Hussain (2004)
10.1016/J.CTRV.2005.03.005
Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
K. Mystakidou (2005)
10.3892/ijo.2013.1845
Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells.
Lidia Luzhna (2013)
10.2147/IJN.S3061
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
E. Miele (2009)
10.1002/9780470960844.CH11
Cancer Prevention by Polyphenols: Influence on Signal Transduction and Gene Expression
Fatima Hakimuddin (2011)
ONCOGÉNICAS RESISTENCIA TERAPÉUTICA DE TUMORES DE MAMA
M. Velazquez (2009)
10.1177/0148607115581838
Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω-3 Polyunsaturated Fatty Acids.
Hongyu Xue (2016)
10.1097/01.blo.0000238787.44349.eb
Multimodality Imaging for Vertebral Metastases in a Rat Osteolytic Model
S. Burch (2007)
10.1007/978-0-387-09463-2_6
Metastasis of hormone receptor positive breast cancer.
M. M. Richert (2009)
10.1185/030079906X115667
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
H. Mouridsen (2006)
10.1002/1878-0261.12375
Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
I. H. Rye (2018)
Validación de nomograma predictivo de afectación ganglionar en pacientes con cáncer de mama e indicación de biopsia selectiva de ganglio centinela (BSGC) en un área de población extremeña
J. M. Rojas (2013)
Investigation of the anti-breast cancer efficacy and mechanisms of disulfiram
P. Liu (2015)
10.2165/00003495-200767050-00002
Oral Vinorelbine
M. Aapro (2012)
10.5772/51506
Isolation of Breast Cancer Stem Cells by Single-Cell Sorting
P. Pham (2012)
10.5772/28902
Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development
S. Sharma (2011)
10.1074/jbc.M116.727727
Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells
Romone M. Fancy (2016)
10.1007/s12282-018-0921-1
Oligometastatic breast cancer
D. Kwapisz (2018)
Changes Of CEA and CA15-3 Biomarkers in the Breast Cancer Patients following eight Weeks of Aerobic Exercise
Azar Esfahbodi (2017)
10.3892/mco.2016.1100
Osteonecrosis of the jaw associated with everolimus: A case report.
D. Yamamoto (2017)
10.1016/j.clbc.2011.11.001
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
M. Strada (2012)
10.4236/JCT.2012.36149
Breast Cancer Therapies Present and Future
J. Kalra (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar